JFS Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.64K | Buy |
21
+2
| +11% | +$251 | ﹤0.01% | 1314 |
|
|
2025
Q1 | $2.1K | Sell |
19
-20
| -51% | -$2.21K | ﹤0.01% | 1450 |
|
|
2024
Q4 | $5.32K | Sell |
39
-1
| -3% | -$137 | ﹤0.01% | 1107 |
|
|
2024
Q3 | $4.61K | Buy |
40
+11
| +38% | +$1.27K | ﹤0.01% | 1151 |
|
|
2024
Q2 | $3.99K | Buy |
29
+14
| +93% | +$1.93K | ﹤0.01% | 1161 |
|
|
2024
Q1 | $2.07K | Hold |
15
| – | – | ﹤0.01% | 1426 |
|
|
2023
Q4 | $1.98K | Buy |
15
+3
| +25% | +$395 | ﹤0.01% | 1445 |
|
|
2023
Q3 | $1.35K | Buy |
12
+2
| +20% | +$225 | ﹤0.01% | 1510 |
|
|
2023
Q2 | $943 | Buy |
10
+6
| +150% | +$566 | ﹤0.01% | 1625 |
|
|
2023
Q1 | $405 | Sell |
4
-3
| -43% | -$304 | ﹤0.01% | 1745 |
|
|
2022
Q4 | $836 | Buy |
7
+2
| +40% | +$239 | ﹤0.01% | 1644 |
|
|
2022
Q3 | $1K | Sell |
5
-6
| -55% | -$1.2K | ﹤0.01% | 1600 |
|
|
2022
Q2 | $1K | Sell |
11
-24
| -69% | -$2.18K | ﹤0.01% | 1590 |
|
|
2022
Q1 | $3K | Buy |
35
+23
| +192% | +$1.97K | ﹤0.01% | 1281 |
|
|
2021
Q4 | $1K | Buy |
+12
| New | +$1K | ﹤0.01% | 1467 |
|
|
2020
Q1 | – | Sell |
-6
| Closed | -$1K | – | 546 |
|
|
2019
Q4 | $1K | Hold |
6
| – | – | ﹤0.01% | 487 |
|
|
2019
Q3 | $1K | Buy |
+6
| New | +$1K | ﹤0.01% | 487 |
|